Inhibition of human and rat 11β-hydroxysteroid dehydrogenase type 1 by 18β-glycyrrhetinic acid derivatives

Journal of Steroid Biochemistry and Molecular Biology

Volumn 104, Issue 3-5, 2007, Pages 312-320

  Su, Xiangdong ^a   Vicker, Nigel ^a   Lawrence, Harshani ^a   Smith, Andrew ^a   Purohit, Atul ^b   Reed, Michael J ^b   Potter, Barry V L ^a  

^a University of Bath   (United Kingdom)

^b Sterix Ltd   (United Kingdom)

Author keywords

11 HSD1; 18 Glycyrrhetinic acid; Hydroxysteroid dehydrogenase; Inhibitors; Metabolic syndrome

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; CARBENOXOLONE; CORTICOSTEROID RECEPTOR; GLYCYRRHETINIC ACID; HYDROCORTISONE;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME INHIBITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; HUMAN; HUMAN CELL; IC 50; LIVER MICROSOME; METABOLIC SYNDROME X; MOLECULAR MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; RADIOIMMUNOASSAY; RAT; SYNTHESIS;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; CARBENOXOLONE; GLYCYRRHETINIC ACID; HUMANS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; MODELS, MOLECULAR; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

RATTUS;

EID: 34250173800     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.03.019     Document Type: Article

References (31)

1. Grundy S.M., Brewer H.B., Cleeman J.I., Smith S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 3 (2004) 433-438
2. Andrew R., Gale C.R., Walker B.R., Seckl J.R., and Martyn C.N. Glucocorticoid metabolism and the metabolic syndrome: associations in an elderly cohort. Exp. Clin. Endocrinol. Diab. 110 (2002) 284-290
3. Walker B.R., Phillips D.I., Noon J.P., Panarelli M., Andrew R., Edwards H.V., Holton D.W., Seckl J.R., Webb D.J., and Watt G.C. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 31 (1998) 891-895
4. Wang M. The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr. Metab. (Lond.) 2 (2005) 3
5. Seckl J.R., and Walker B.R. Minireview: 11ß-hydroxysteroid dehydrogenase type 1-a tissue-specific amplifier of glucocorticoid action. Endocrinology 142 (2001) 1371-1376
6. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., and Sutano W.S. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 332 (1988) 986-989
7. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., and Stewart P.M. 11β-Hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 25 (2004) 831-866
8. Kotelevtsev Y.V., Brown R.W., Fleming S., Kenyon C., Edwards C.R.W., Seckl J.R., and Mullins J.J. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103 (1999) 683-689
9. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. Science 294 (2001) 2166-2170
10. Walker B.R., Connacher A.A., Lindsay M., Webb D.J., and Edwards C.R.W. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80 (1995) 3155-3159
11. Fotsch C., Askew B.C., and Chen J.J. 11β-Hydroxysteroid dehydrogenase-1 as a target for metabolic diseases. Expert Opin. Ther. Pat. 54 (2005) 289-303
12. Agarwal A.K., Mune T., Monder C., and White P.C. NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J. Biol. Chem. 269 (1994) 25959-25962
13. Kotelevtsev Y., Brown R.W., Fleming S., Kenyon C., Edwards C.R.W., Seckl J.R., and Mullins J.J. Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 103 (1999) 683-689
14. Ferrari P., Sansonnens A., Dick B., and Frey F.J. In vivo 11β-HSD 2 activity: variability, salt-sensitivity and effect of licorice. Hypertension 38 (2001) 1330-1336
15. Monder C., Stewart P.M., Lakshmi V., Valentino R., Burt D., and Edwards C.R.W. Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinol 125 (1989) 1046-1053
16. Buhler H., Perschel F.H., and Hierholzer K. Inhibition of rat renal 11β-hydroxysteroid dehydrogenase by steroidal compounds and triterpenoids: structure/function relationship. Biochim. Biophys. Acta 1075 (1991) 206-212
17. Nacamulli D.A.D., Francini-Pesenti F., Battagin G., Ragazzi E., and Fiore C. Glycyrrhetinic acid, the active principle of licorice, can reduce the thickness of subcutaneous thigh fat through topical application. Steroids 70 (2005) 538-542
18. B.V.L. Potter, A. Purohit, M.J. Reed, N. Vicker, Use of glycyrrhetinic acid and progesterone derivatives which inhibit 11β-hydroxysteroid dehydrogenase as medicaments, PCT Int. Appl. WO072084 (2002).
19. Vicker N., Su X., Lawrence H., Cruttenden A., Purohit A., Reed M.J., and Potter B.V.L. A novel 18β-glycyrrhetinic acid analogue as a potent and selective inhibitor of 11β-hydroxysteroid dehydrogenase 2. Bioorg. Med. Chem. Lett. 14 (2004) 3263-3267
20. Su X., Lawrence H., Ganeshapillai D., Cruttenden A., Purohit A., Reed M.J., and Potter B.V.L. Novel 18β-glycyrrhetinic acid analogues as potent and selective inhibitors of 11β-hydroxysteroid dehydrogenases. Bioorg. Med. Chem. 12 (2004) 4439-4457
21. Hosfield D.J., Wu Y., Skene E.J., Hilgers M., Jennings A., Snell G.P., and Aertgeerts K. Conformational flexibility in crystal structures of human 11β-hydroxysteroid dehydrogenase type I provide insights into glucocorticoid interconversion and enzyme regulation. J. Biol. Chem. 280 (2005) 4639-4648
22. Vicker N., Su X., Ganeshapillai D., Purohit A., Reed M.J., and Potter B.V.L. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2. PCT Int. Appl. WO037251 (2004)
23. Jones G., Willett P., Glen R.C., Leach A.R., and Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267 (1997) 727-748
24. Halgren A. MMFF VII characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J. Comp. Chem. 20 (1999) 730-748
25. Sybyl Version 7.0, Tripos Inc., 1699 South Hanley RD, St. Louis, Missouri 63144, USA.
26. Yoshihito S., Kazuhiro H., Hiroatsu M., Toshitsugu S., Shoji S., and Hideo I. Effects of glycyrrhetinic acid derivatives on hepatic and renal 11β-hydroxysteroid dehydrogenase activities in rats. J. Pharm. Pharmacol. 55 6 (2003) 811-817
27. Barf T., Vallgårda J., Emond R., Häggstrom G.K., Nygren A., Larwood V., Mosialou E., Axelsson K., Olsson R., Engblom L., Edling N., Rönquist-Nii Y., Öhman B., Alberts P., and Abrahmsén L. Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J. Med. Chem. 45 (2002) 3813-3815
28. Hult M., Shafqat N., Elleby B., Mitschke D., Svensson S., Forsgren M., Barf T., Vallgårda J., Abrahmsen L., and Oppermann U. Active site variability of type 1 11β-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol. Cell. Endocrinol. 248 (2006) 26-33
29. Arampatzis S., Kadereit B., Schuster D., Balazs Z., Schweizer R.A., Frey F.J., Langer T., and Odermatt A. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J. Mol. Endocrinol. 35 (2005) 89-101
30. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucleic Acids Res. 28 (2000) 235-242
31. Degraffenreid M.R., He X., Powers J.P., Sun D., and Yan X. Preparation of aryl sulfonamides as inhibitors of hydroxysteroid dehydrogenases (HSDs). PCT Int. Appl. WO063247 (2005)